You are here

IDO inhibitors

#ASCO18: Don’t write off IDO yet, says NewLink

Fierce Biotech

Mon, 06/4/18 - 10:19 pm

NewLink Genetics

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

Xconomy

Thu, 05/31/18 - 08:17 pm

Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination

Fierce Biotech

Wed, 05/2/18 - 09:55 am

Incyte's Horrible News Derails a Promising Class of Cancer Drugs

Motley Fool

Fri, 04/6/18 - 07:43 pm

NewLink Genetics

5 Game-Changing Cancer Drug Innovations Being Developed Right Now

Motley Fool

Thu, 10/12/17 - 10:45 am

cancer immunotherapies

T-cell receptors

TCR therapeutics

Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for

Endpoints

Tue, 05/30/17 - 11:48 am

PDL-1 inhibitors

NewLink Genetics

Juno Therapeutics

Bristol-Myers Squibb